相关实验视频

Updated: Jul 11, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

SARS-CoV-2 导致大脑损伤:使用 AZD8797的治疗干预

Elif Kervancioglu Demirci¹, Engin Alp Onen², Erva Sevic Yilmaz¹

¹Histology and Embryology Department, Istanbul Faculty of Medicine, Istanbul University, Turgut Ozal Cd. No:118m, Capa-Fatih, Istanbul 34093, Turkey.

Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada

|November 15, 2023

概括

CX3CL1-CX3CR1通路可能会恶化COVID-19的神经损伤. 作为CX3CR1抗剂的AZD8797在小鼠中显示出保护作用,减少神经元损伤并改善记忆力. 为了临床应用,需要进一步的研究.

科学领域:

神经科学是一个神经科学.
病毒学病毒学
药理学药理学是一个学科.

背景情况:

较高的CX3CL1水平与严重的COVID-19和神经系统并发症相关.
CX3CL1-CX3CR1信号通路与神经炎症和病毒病原发生有关.

研究的目的:

评估CX3CR1对手AZD8797对抗SARS-CoV-2诱导的神经元损伤的神经保护潜力.
在小鼠模型中阐明AZD8797作用的潜在机制.

主要方法:

转基因K18-hACE2小鼠暴露在SARS-CoV-2中,并用AZD8797或载体进行治疗.
用对象识别和洞板测试来评估认知功能.
脑组织和血清被分析为组织病理学,病毒载荷,质激活,亡,氧化应激标志物和细胞因子.

主要成果:

感染SARS-CoV-2导致体重减轻,神经元损伤,氧化应激和记忆障碍.
AZD8797治疗部分扭转了这些影响,改善了体重,减少了亡,并提高了谷氨水平.
组织病理学分析证实了AZD8797对抗SARS-CoV-2诱导的大脑损伤的保护作用.

结论:

CX3CL1-CX3CR1通路是缓解SARS-CoV-2神经后果的潜在治疗标.
在COVID-19的临床前模型中,AZD8797显示出有前途的神经保护作用.
需要进一步的研究来证实临床疗效,并探索组合疗法.

关键词:

在 COVID-19 疫情中,在CX3CL1中.组织学组织学氧化应激是一种氧化应激.转基因小鼠转基因小鼠

更多相关视频

Controlled Cortical Impact Model for Traumatic Brain Injury

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...